ABSTRACT
Background and study aims In 2019, the European Society of Gastrointestinal Endoscopy (ESGE) created a working group to develop technical and quality standards for small-bowel capsule endoscopy (SBCE) to improve the daily practice of endoscopy services. They developed 10 quality parameters, which have yet to be tested in a real-life setting. Our study aimed to evaluate the accomplishment of the quality standards in SBCE established by the ESGE in several Spanish centers. Materials and methods An online survey of 11 multiple-choice questions related to the ESGE performance measures was sent to Spanish centers with experience in SBCE. In order to participate and obtain reliable data, at least 100 questionnaires had to be answered per center because that is the minimum number established by ESGE. Results 20 centers participated in the study, compiling 2049 SBCEs for the analysis. Only one of 10 performance measures (cecal visualization) reached the minimum standard established by the ESGE. In five of 10 performance measures (Indication, lesion detection rate, terminology, and retention rate) the minimum standard was nearly achieved. Conclusions Our study is the first multicenter study regarding SBCE quality performance measures in a real setting. Our results show that the minimum standard is hardly reached in most procedures, which calls into question their clinical applicability in real life. We suggest performing similar studies in other countries to evaluate whether there is a need for quality improvement programs or a need to reevaluate the minimum and target values published so far.
ABSTRACT
Small bowel carcinoid tumor is a difficult to diagnose entity that can present an aggressive clinical course even if they are small in size. The diagnosis based on tumor markers and imaging tests is limited, but the combination of capsule endoscopy followed by enteroscopy when the carcinoid tumor is suspected, has been shown to be useful for its early diagnosis, as well as for reaching a thorough study of the small bowel. We present a clinical case of two small synchronous carcinoid tumors of the ilium that were diagnosed by using this strategy.
Subject(s)
Capsule Endoscopy , Carcinoid Tumor , Intestinal Neoplasms , Carcinoid Tumor/diagnostic imaging , Gastrointestinal Hemorrhage , Humans , Intestinal Neoplasms/diagnostic imaging , Intestine, Small/diagnostic imagingABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Hemangioma, Cavernous/diagnostic imaging , Jejunal Neoplasms/diagnostic imaging , Anemia, Iron-Deficiency/etiology , Hemangioma, Cavernous/complications , Jejunal Neoplasms/pathology , Anemia, Iron-Deficiency/diagnosis , Gastroscopy , Biopsy , Colonoscopy , Tomography, X-Ray Computed , Balloon EnteroscopyABSTRACT
BACKGROUND: Acute gastrointestinal bleeding is prevalent condition and iron deficiency anaemia is a common comorbidity, yet anaemia treatment guidelines for affected patients are lacking. AIM: To compare efficacy and safety of intravenous ferric carboxymaltose (FCM) and oral ferrous sulphate (FeSulf) in patients with anaemia secondary to non-variceal gastrointestinal bleeding METHODS: A prospective 42-day study randomised 61 patients with haemoglobin <10 g/dL upon discharge (Day 0) to receive FCM (n = 29; Day 0: 1000 mg, Day 7: 500 or 1000 mg; per label) or FeSulf (n = 32; 325 mg/12 hours for 6 weeks). Outcome measures were assessed on Days 0 (baseline), 7, 21 and 42. The primary outcome was complete response (haemoglobin ≥12 g/dL [women], ≥13 g/dL [men]) after 6 weeks. RESULTS: A higher proportion of complete response was observed in the FCM vs the FeSulf group at Days 21 (85.7% vs 45.2%; P = 0.001) and 42 (100% vs 61.3%; P < 0.001). Additionally, the percentage of patients with partial response (haemoglobin increment ≥2 g/dL from baseline) was significantly higher in the FCM vs the FeSulf group (Day 21:100% vs 67.7%; P = 0.001, Day 42:100% vs 74.2%; P = 0.003). At Day 42, normalisation of transferrin saturation to 25% or greater was observed in 76.9% of FCM vs 24.1% of FeSulf-treated patients (P < 0.001). No patient in the FCM group reported any adverse event vs 10 patients in the FeSulf group. CONCLUSION: FCM provided greater and faster Hb increase and iron repletion, and was better tolerated than FeSulf in patients with iron deficiency anaemia secondary to non-variceal acute gastrointestinal bleeding.
Subject(s)
Anemia, Iron-Deficiency/drug therapy , Anemia, Iron-Deficiency/etiology , Gastrointestinal Hemorrhage/complications , Gastrointestinal Hemorrhage/drug therapy , Iron/administration & dosage , Acute Disease , Administration, Intravenous , Administration, Oral , Adult , Aged , Aged, 80 and over , Female , Humans , Iron/adverse effects , Male , Middle Aged , Prospective Studies , Treatment OutcomeABSTRACT
No disponible
Subject(s)
Humans , Digestive System Diseases/diagnostic imaging , Capsule Endoscopy/adverse effects , Iatrogenic Disease/prevention & control , Capsule Endoscopy/statistics & numerical data , Risk FactorsABSTRACT
We read the papers by Juanmartiñena et al. entitled "Colonic lesions in patients undergoing small bowel capsule endoscopy: incidence, diagnostic and therapeutic impact" and "Gastroduodenal lesions detected during small bowel capsule endoscopy: incidence, diagnostic and therapeutic impact".
Subject(s)
Capsule Endoscopy , Colonic Diseases , Humans , Incidence , Intestine, SmallABSTRACT
BACKGROUND: Capsule endoscopy (CE) is the first-line investigation in cases of suspected Crohn's disease (CD) of the small bowel, but the factors associated with a higher diagnostic yield remain unclear. OBJECTIVE: Our aim is to develop and validate a scoring index to assess the risk of the patients in this setting on the basis of biomarkers. PATIENTS AND METHODS: Data on fecal calprotectin, C-reactive protein, and other biomarkers from a population of 124 patients with suspected CD of the small bowel studied by CE and included in a PhD study were used to build a scoring index. This was first used on this population (internal validation process) and after that on a different set of patients from a multicenter study (external validation process). RESULTS: An index was designed in which every biomarker is assigned a score. Three risk groups have been established (low, intermediate, and high). In the internal validation analysis (124 individuals), patients had a 10, 46.5, and 81% probability of showing inflammatory lesions in CE in the low-risk, intermediate-risk, and high-risk groups, respectively. In the external validation analysis, including 410 patients from 12 Spanish hospitals, this probability was 15.8, 49.7, and 80.6% for the low-risk, intermediate-risk, and high-risk groups, respectively. CONCLUSION: Results from the internal validation process show that the scoring index is coherent, and results from the external validation process confirm its reliability. This index can be a useful tool for selecting patients before CE studies in cases of suspected CD of the small bowel.
Subject(s)
Capsule Endoscopy/methods , Crohn Disease/diagnosis , Intestine, Small/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers/analysis , C-Reactive Protein/analysis , Capsule Endoscopy/adverse effects , Child , Child, Preschool , Feces/chemistry , Female , Humans , Leukocyte L1 Antigen Complex/analysis , Male , Middle Aged , Predictive Value of Tests , Reproducibility of Results , Risk Assessment/methods , Sensitivity and Specificity , Young AdultABSTRACT
BACKGROUND AND AIM: The role of capsule endoscopy (CE) in established celiac disease (CD) remains unclear. Our objective was to analyze the usefulness of CE in the suspicion of complicated CD. METHODS: This was a retrospective multicenter study. One hundred and eighty-nine celiac patients (mean age: 46.6 ± 16.6, 30.2% males) who underwent CE for alarm symptoms (n = 86, 45.5%) or non-responsive CD (n = 103, 54.5%) were included. Diagnostic yield (DY), therapeutic impact and safety were analyzed. RESULTS: Capsule endoscopy was completed in 95.2% of patients (small bowel transit time: 270.5 ± 100.2 min). Global DY was 67.2%, detecting atrophic mucosa (n = 92, 48.7%), ulcerative jejunoileitis (n = 21, 11.1%), intestinal lymphoma (n = 7, 3.7%) and other enteropathies (n = 7, 3.7%, six Crohn's disease cases and one neuroendocrine tumor). The DY of CE was significantly higher in patients presenting with non-responsive disease compared to patients with alarm symptoms (73.8% vs 59.3%, P = 0.035). The new findings of the CE modified management in 59.3% of the cases. There were no major complications. CONCLUSION: Capsule endoscopy may be a moderately helpful and safe diagnostic tool in the suspicion of complicated CD, modifying the clinical course of these patients.
Subject(s)
Capsule Endoscopy/methods , Celiac Disease/diagnosis , Diet, Gluten-Free , Intestinal Mucosa/pathology , Adult , Celiac Disease/diet therapy , Cohort Studies , Disease Progression , Female , Follow-Up Studies , Humans , Intestine, Small/pathology , Intestine, Small/physiopathology , Male , Middle Aged , Retrospective Studies , Risk Assessment , Severity of Illness Index , Young AdultABSTRACT
AIM: To analyze the diagnostic yield (DY), therapeutic impact (TI) and safety of capsule endoscopy (CE). METHODS: This is a multi-centre, observational, analytical, retrospective study. A total of 163 patients with suspicion of celiac disease (CD) (mean age = 46.4 ± 17.3 years, 68.1% women) who underwent CE from 2003 to 2015 were included. Patients were divided into four groups: seronegative CD with atrophy (Group-I, n = 19), seropositive CD without atrophy (Group-II, n = 39), contraindication to gastroscopy (Group-III, n = 6), seronegative CD without atrophy, but with a compatible context (Group-IV, n = 99). DY, TI and the safety of CE were analysed. RESULTS: The overall DY was 54% and the final diagnosis was villous atrophy (n = 65, 39.9%), complicated CD (n = 12, 7.4%) and other enteropathies (n = 11, 6.8%; 8 Crohn's). DY for groups I to IV was 73.7%, 69.2%, 50% and 44.4%, respectively. Atrophy was located in duodenum in 24 cases (36.9%), diffuse in 19 (29.2%), jejunal in 11 (16.9%), and patchy in 10 cases (15.4%). Factors associated with a greater DY were positive serology (68.3% vs 49.2%, P = 0.034) and older age (P = 0.008). On the other hand, neither sex nor clinical presentation, family background, positive histology or HLA status were associated with DY. CE results changed the therapeutic approach in 71.8% of the cases. Atrophy was associated with a greater TI (92.3% vs 45.3%, P < 0.001) and 81.9% of the patients responded to diet. There was one case of capsule retention (0.6%). Agreement between CE findings and subsequent histology was 100% for diagnosing normal/other conditions, 70% for suspected CD and 50% for complicated CD. CONCLUSION: CE has a high DY in cases of suspicion of CD and it leads to changes in the clinical course of the disease. CE is safe procedure with a high degree of concordance with histology and it helps in the differential diagnosis of CD.
Subject(s)
Capsule Endoscopy , Celiac Disease/diagnostic imaging , Gastroscopy , Adolescent , Adult , Aged , Aged, 80 and over , Atrophy , Child , Diet, Gluten-Free , Europe , Female , Humans , Male , Middle Aged , Patient Safety , Prevalence , Retrospective Studies , Young AdultABSTRACT
Capsule endoscopy (CE) currently plays an important role in Crohn's disease (CD). It is a noninvasive technique that has led to a breakthrough in the endoscopic diagnosis of diseases of the small intestine. Its superior diagnostic performance and excellent safety profile lead to its considerable acceptance on the part of the patient. This paper reviews current indications of CE in three stages of clinical practice: Suspected CD, unclassified colitis and its extensive role in diagnosed CD. The diagnostic and therapeutic impact of the results of CE on the monitoring of this disease is also reviewed. Knowledge of its applications, the interpretation of its results in an appropriate context and the existence of a validated endoscopic activity index could change the way in which these patients are managed. The definition of mucosal healing and postoperative recurrence by means of endoscopic scoring systems will endow CE with new applications in the management of CD in the near future.
ABSTRACT
El pseudoaneurisma asociado a pseudoquiste es una complicación grave e infrecuente de la pancreatitis crónica. Su tratamiento es complejo por su elevada mortalidad y la necesidad de un manejo multidisciplinar. La medida inicial consiste en la localización de la hemorragia mediante tomografía computarizada dinámica y arteriografía. El tratamiento de elección es controvertido por la ausencia de estudios controlados. Para el manejo de la hemorragia en pacientes estables, la medida terapéutica inicial más aceptada actualmente es la embolización arterial. Ante fracaso de la misma, inestabilidad hemodinámica o imposibilidad de drenaje del pseudoquiste la cirugía es la siguiente opción terapéutica (AU)
A pseudoaneurysm associated with a pseudocyst is a serious and unusual complication of chronic pancreatitis. Its treatment is complex due to its elevated mortality and the need for multidisciplinary management. Initial measures consist in locating the hemorrhage through computerized dynamic tomography and arteriography. The treatment of choice is controversial due to the lack of controlled studies. For managing hemorrhages in stable patients, the most accepted initial measure currently is arterial embolization. In the event of failure of the same, hemodynamic instability or the impossibility of drainage of the pseudocyst, surgery is the subsequent therapeutic option(AU)
Subject(s)
Humans , Male , Adult , Pancreatic Pseudocyst/complications , Aneurysm, False/complications , Pancreatitis, Chronic/complications , Gastrointestinal Hemorrhage/etiology , Endoscopy, Digestive SystemABSTRACT
A pseudoaneurysm associated with a pseudocyst is a serious and unusual complication of chronic pancreatitis. Its treatment is complex due to its elevated mortality and the need for multidisciplinary management. Initial measures consist in locating the hemorrhage through computerized dynamic tomography and arteriography. The treatment of choice is controversial due to the lack of controlled studies. For managing hemorrhages in stable patients, the most accepted initial measure currently is arterial embolization. In the event of failure of the same, hemodynamic instability or the impossibility of drainage of the pseudocyst, surgery is the subsequent therapeutic option.
Subject(s)
Aneurysm, False/complications , Pancreatic Pseudocyst/complications , Adult , Aneurysm, False/diagnostic imaging , Aneurysm, False/therapy , Cholangiography , Embolization, Therapeutic , Humans , Magnetic Resonance Imaging , Male , Pancreatic Pseudocyst/diagnostic imaging , Pancreatic Pseudocyst/therapy , Pancreatitis, Chronic/chemically induced , Pancreatitis, Chronic/complications , Pancreatitis, Chronic/diagnostic imaging , Treatment OutcomeABSTRACT
Achalasia is an oesophageal motor disorder which leads to the functional obstruction of the lower oesophageal sphincter (LES) and is currently incurable. The main objective of all existing therapies is to achieve a reduction in the obstruction of the distal oesophagus in order to improve oesophageal transit, relieve the symptomatology, and prevent long-term complications. The most common treatments used are pneumatic dilation (PD) and laparoscopic Heller myotomy, which involves partial fundoplication with comparable short-term success rates. The most economic non-surgical therapy is PD, with botulinum toxin injections reserved for patients with a higher surgical risk for whom the former treatment option is unsuitable. A new technology is peroral endoscopic myotomy, postulated as a possible non-invasive alternative to surgical myotomy. Other endoluminal treatments subject to research more recently include injecting ethanolamine into the LES and using a temporary self-expanding metallic stent. At present, there is not enough evidence permitting a routine recommendation of any of these three novel methods. Patients must undergo follow-up after treatment to guarantee that their symptoms are under control and to prevent complications. Most experts are in favour of some form of endoscopic follow-up, however no established guidelines exist in this respect. The prognosis for patients with achalasia is good, although a recurrence after treatment using any method requires new treatment.
ABSTRACT
Capsule endoscopy currently plays a relevant role for Crohn´s disease. This manuscript will discuss the current indications and practical uses of capsule endoscopy in this disease. It is a non-invasive technique that represents a significant advance in the endoscopic diagnosis of small bowel conditions. These circumstances, together with its diagnostic yield and excellent tolerability, make it considerably acceptable by both patients and physicians. This paper discusses the current evidence on the specific circumstances where capsule endoscopy may be indicated for three specific scenarios: Suspected Crohn´s disease, indeterminate colitis, and established Crohn´s disease, where it plays an extensive role. Furthermore, the impact and implications of capsule endoscopy results for follow-up are reviewed. These recommendations must be interpreted and applied in the setting of the integral, individual management of these patients. Understanding its appropriate use in daily clinical practice and an analysis of results may define endoscopic scoring systems to assess activity and mucosal healing in this condition. The present role of capsule endoscopy for Crohn´s disease is subject to ongoing review, and appropriate usage uncovers novel applications likely to result in relevant changes for the future management of these patients.
Subject(s)
Capsule Endoscopy/methods , Crohn Disease/diagnosis , Capsule Endoscopes , Capsule Endoscopy/adverse effects , Crohn Disease/therapy , HumansABSTRACT
Actualmente la cápsula endoscópica tiene un papel relevante en la enfermedad de Crohn. Este manuscrito pretende dar a conocer las indicaciones y aplicaciones prácticas actuales de la cápsula endoscópica en esta enfermedad. Se trata de una técnica no invasiva que ha supuesto un importante avance en el diagnóstico endoscópico de las enfermedades del intestino delgado. Estas circunstancias, junto a su rendimiento diagnóstico y su excelente tolerancia, le confieren una considerable aceptación por parte del paciente y del médico. Este artículo expone la evidencia actual acerca las circunstancias específicas en las que se puede establecer la indicación de la cápsula endoscópica en tres escenarios concretos: en la sospecha de la enfermedad de Crohn, en las colitis sin clasificar y su extenso papel en la enfermedad de Crohn ya establecida. Así mismo, se revisan el impacto y la implicación de los resultados de la cápsula endoscópica en el seguimiento de esta enfermedad. Estas recomendaciones deben ser interpretadas y aplicadas en el contexto de un manejo integral e individual de estos pacientes. El conocimiento de su correcto uso en la práctica clínica diaria y el análisis de sus resultados podrían dar lugar a la definición de sistemas de puntuación endoscópica que evalúen la actividad y curación mucosa de esta enfermedad. El papel actual de la cápsula endoscópica en la enfermedad de Crohn es objeto de continua revisión y su adecuado uso le dota de nuevas aplicaciones, que podrían en un futuro dar lugar a cambios relevantes en el manejo de estos pacientes (AU)
Capsule endoscopy currently plays a relevant role for Crohns disease. This manuscript will discuss the current indications and practical uses of capsule endoscopy in this disease. It is a non-invasive technique that represents a significant advance in the endoscopic diagnosis of small bowel conditions. These circumstances, together with its diagnostic yield and excellent tolerability, make it considerably acceptable by both patients and physicians. This paper discusses the current evidence on the specific circumstances where capsule endoscopy may be indicated for three specific scenarios: Suspected Crohns disease, indeterminate colitis, and established Crohns disease, where it plays an extensive role. Furthermore, the impact and implications of capsule endoscopy results for follow-up are reviewed. These recommendations must be interpreted and applied in the setting of the integral, individual management of these patients. Understanding its appropriate use in daily clinical practice and an analysis of results may define endoscopic scoring systems to assess activity and mucosal healing in this condition. The present role of capsule endoscopy for Crohns disease is subject to ongoing review, and appropriate usage uncovers novel applications likely to result in relevant changes for the future management of these patients (AU)
